520 related articles for article (PubMed ID: 12145779)
1. Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration.
Chan DC; Watts GF; Redgrave TG; Mori TA; Barrett PH
Metabolism; 2002 Aug; 51(8):1041-6. PubMed ID: 12145779
[TBL] [Abstract][Full Text] [Related]
2. Apolipoproteins C-III and A-V as predictors of very-low-density lipoprotein triglyceride and apolipoprotein B-100 kinetics.
Chan DC; Watts GF; Nguyen MN; Barrett PH
Arterioscler Thromb Vasc Biol; 2006 Mar; 26(3):590-6. PubMed ID: 16410456
[TBL] [Abstract][Full Text] [Related]
3. Hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 studied with a stable isotope technique in men with visceral obesity.
Riches FM; Watts GF; Naoumova RP; Kelly JM; Croft KD; Thompson GR
Int J Obes Relat Metab Disord; 1998 May; 22(5):414-23. PubMed ID: 9622338
[TBL] [Abstract][Full Text] [Related]
4. Reduction in visceral adipose tissue is associated with improvement in apolipoprotein B-100 metabolism in obese men.
Riches FM; Watts GF; Hua J; Stewart GR; Naoumova RP; Barrett PH
J Clin Endocrinol Metab; 1999 Aug; 84(8):2854-61. PubMed ID: 10443691
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of action of a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesity.
Chan DC; Watts GF; Barrett PH; Mori TA; Beilin LJ; Redgrave TG
J Clin Endocrinol Metab; 2002 May; 87(5):2283-9. PubMed ID: 11994377
[TBL] [Abstract][Full Text] [Related]
6. Randomized controlled trial of the effect of n-3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity.
Chan DC; Watts GF; Mori TA; Barrett PH; Redgrave TG; Beilin LJ
Am J Clin Nutr; 2003 Feb; 77(2):300-7. PubMed ID: 12540386
[TBL] [Abstract][Full Text] [Related]
7. Plasma apolipoprotein C-III transport in centrally obese men: associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolism.
Chan DC; Nguyen MN; Watts GF; Barrett PH
J Clin Endocrinol Metab; 2008 Feb; 93(2):557-64. PubMed ID: 18000086
[TBL] [Abstract][Full Text] [Related]
8. Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia.
Chan DC; Watts GF; Barrett PH; Beilin LJ; Redgrave TG; Mori TA
Diabetes; 2002 Aug; 51(8):2377-86. PubMed ID: 12145148
[TBL] [Abstract][Full Text] [Related]
9. Very low density lipoprotein metabolism and plasma adiponectin as predictors of high-density lipoprotein apolipoprotein A-I kinetics in obese and nonobese men.
Chan DC; Barrett PH; Ooi EM; Ji J; Chan DT; Watts GF
J Clin Endocrinol Metab; 2009 Mar; 94(3):989-97. PubMed ID: 19116237
[TBL] [Abstract][Full Text] [Related]
10. Apolipoprotein B-100 kinetics and static plasma indices of triglyceride-rich lipoprotein metabolism in overweight men.
Chan DC; Watts GF; Ng TW; Uchida Y; Sakai N; Yamashita S; Barrett PH
Clin Biochem; 2005 Sep; 38(9):806-12. PubMed ID: 15992790
[TBL] [Abstract][Full Text] [Related]
11. Plasma markers of cholesterol homeostasis and apolipoprotein B-100 kinetics in the metabolic syndrome.
Chan DC; Watts GF; Barrett PH; O'Neill FH; Thompson GR
Obes Res; 2003 Apr; 11(4):591-6. PubMed ID: 12690090
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.
Ooi EM; Watts GF; Sprecher DL; Chan DC; Barrett PH
J Clin Endocrinol Metab; 2011 Oct; 96(10):E1568-76. PubMed ID: 21816786
[TBL] [Abstract][Full Text] [Related]
13. In-vivo metabolism of VLDL-apolipoprotein-B, -CIII and -E in normolipidemic subjects.
Dinkel RE; Barrett PH; Demant T; Parhofer KG
Nutr Metab Cardiovasc Dis; 2006 Apr; 16(3):215-21. PubMed ID: 16580589
[TBL] [Abstract][Full Text] [Related]
14. Markers of triglyceride-rich lipoprotein remnant metabolism in visceral obesity.
Chan DC; Watts GF; Barrett PH; Mamo JC; Redgrave TG
Clin Chem; 2002 Feb; 48(2):278-83. PubMed ID: 11805008
[TBL] [Abstract][Full Text] [Related]
15. Plasma apolipoprotein C-III metabolism in patients with chronic kidney disease.
Ooi EM; Chan DT; Watts GF; Chan DC; Ng TW; Dogra GK; Irish AB; Barrett PH
J Lipid Res; 2011 Apr; 52(4):794-800. PubMed ID: 21297177
[TBL] [Abstract][Full Text] [Related]
16. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG
Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
[TBL] [Abstract][Full Text] [Related]
17. Adipose tissue compartments and the kinetics of very-low-density lipoprotein apolipoprotein B-100 in non-obese men.
Watts GF; Chan DC; Barrett PH
Metabolism; 2002 Sep; 51(9):1206-10. PubMed ID: 12200768
[TBL] [Abstract][Full Text] [Related]
18. ATP-binding cassette transporter G8 gene as a determinant of apolipoprotein B-100 kinetics in overweight men.
Chan DC; Watts GF; Barrett PH; Whitfield AJ; van Bockxmeer FM
Arterioscler Thromb Vasc Biol; 2004 Nov; 24(11):2188-91. PubMed ID: 15331430
[TBL] [Abstract][Full Text] [Related]
19. Early kinetic abnormalities of apoB-containing lipoproteins in insulin-resistant women with abdominal obesity.
Pont F; Duvillard L; Florentin E; Gambert P; Vergès B
Arterioscler Thromb Vasc Biol; 2002 Oct; 22(10):1726-32. PubMed ID: 12377756
[TBL] [Abstract][Full Text] [Related]
20. Effects of ApoE genotype on ApoB-48 and ApoB-100 kinetics with stable isotopes in humans.
Welty FK; Lichtenstein AH; Barrett PH; Jenner JL; Dolnikowski GG; Schaefer EJ
Arterioscler Thromb Vasc Biol; 2000 Jul; 20(7):1807-10. PubMed ID: 10894821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
